Viking Therapeutics (VKTX) Change in Account Payables (2014 - 2026)

Viking Therapeutics has reported Change in Account Payables for 13 years, with the latest figure at $1.8 million in Q2 2026.

• Quarterly Change in Account Payables rose 182.84% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $63.5 million (up 1235.67% YoY) and the FY2025 annual result came in at $43.4 million, up 1786.15% from the prior year.
• Change in Account Payables slipped to $1.8 million in Q2 2026 per VKTX's latest filing, from $13.9 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $48.8 million in Q4 2025 and troughed at -$10.8 million in Q3 2024.
• A 5-year average of $3.8 million and a median of $1.8 million in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2026: Change in Account Payables plunged 10935.0% in 2024, then surged 760.24% in 2026.
• Over 5 years, Change in Account Payables stood at $5.4 million in 2022, then plunged by 66.57% to $1.8 million in 2023, then jumped by 430.87% to $9.6 million in 2024, then surged by 410.8% to $48.8 million in 2025, then slumped by 96.25% to $1.8 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.8 million, $13.9 million, and $48.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.